BR9809124A - Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente - Google Patents

Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente

Info

Publication number
BR9809124A
BR9809124A BR9809124-7A BR9809124A BR9809124A BR 9809124 A BR9809124 A BR 9809124A BR 9809124 A BR9809124 A BR 9809124A BR 9809124 A BR9809124 A BR 9809124A
Authority
BR
Brazil
Prior art keywords
purin
amino
combination
cyclopropylamino
cyclopentene
Prior art date
Application number
BR9809124-7A
Other languages
English (en)
Inventor
Martha Heider St Clair
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719866.7A external-priority patent/GB9719866D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9809124A publication Critical patent/BR9809124A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçãO, FORMULAçãO FARMACêUTICA, PROCESSO PARA O TRATAMENTO DE UMA INFECçãO POR HIV EM UM ANIMAL INFECTADO, USO DE (-)-(1S, 4R)-4-[2-AMINO-6-(CICLOPROPILAMINO)-9H-PURIN-9-IL)-2-CICL OPENTENO-1-METANOL, E, PACOTE DE PACIENTE". A presente invenção refere-se à combinação terapêutica de (-)-(1S, 4R)-4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-m etanol (1592U89) e inibidores da protease HIV que têm atividade anti-HIV. A presente invenção ocupa-se também das composições farmacêuticas contendo ditas combinações e a seu uso no tratamento de infecções por HIV.
BR9809124-7A 1997-05-17 1998-05-14 Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente BR9809124A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719866.7A GB9719866D0 (en) 1997-09-19 1997-09-19 Antiviral Combinations
PCT/EP1998/002837 WO1998052571A1 (en) 1997-05-17 1998-05-14 Antiviral combinations containing the carbocyclic nucleoside 1592u89

Publications (1)

Publication Number Publication Date
BR9809124A true BR9809124A (pt) 2000-08-01

Family

ID=26311542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809124-7A BR9809124A (pt) 1997-05-17 1998-05-14 Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente

Country Status (8)

Country Link
EP (1) EP1019056A1 (pt)
JP (1) JP2001525840A (pt)
AU (1) AU8017298A (pt)
BR (1) BR9809124A (pt)
CA (1) CA2289654A1 (pt)
NO (1) NO995621L (pt)
NZ (1) NZ500868A (pt)
WO (1) WO1998052571A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
JP2005508940A (ja) * 2001-10-05 2005-04-07 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なアリルアミド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
CA2243121A1 (en) * 1996-01-26 1997-07-31 Francesco Gerald Salituro Aspartyl protease inhibitors
US6486136B1 (en) * 1996-06-25 2002-11-26 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV

Also Published As

Publication number Publication date
WO1998052571A1 (en) 1998-11-26
AU8017298A (en) 1998-12-11
JP2001525840A (ja) 2001-12-11
NZ500868A (en) 2001-08-31
NO995621D0 (no) 1999-11-16
CA2289654A1 (en) 1998-11-26
EP1019056A1 (en) 2000-07-19
NO995621L (no) 2000-01-14

Similar Documents

Publication Publication Date Title
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
BR9810745A (pt) Derivados de benzimidazol
BG101118A (en) Therapeutical compounds
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR9607851A (pt) Combinaçao que compreende dois compostos formulaçao farmacêutica processo para o tratamento ou a prevençao de sintomas ou efeitos de uma infecçao por hiv em um animal infectado utilizaçao embalagem para um paciente
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
PT914110E (pt) Metodo de modulacao da micro-circulacao
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR9916893A (pt) Tratamento
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
NO970847L (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
CO4520283A1 (es) Agentes antivirales
BR0308293A (pt) Terapia à base de estatina para aumentar a manutenção cognitiva
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
BR0115506A (pt) Composições farmacêuticas tendo uma ação antidiabética, e processo para sua preparação
HUP9903098A2 (hu) VX478, zidovudin és/vagy 1592U89 kombinációja és ezt tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired